Logo image of INTS

INTENSITY THERAPEUTICS INC (INTS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INTS - US45828J1034 - Common Stock

0.4066 USD
-0.01 (-2.73%)
Last: 12/24/2025, 1:35:43 PM
0.4083 USD
+0 (+0.42%)
After Hours: 12/24/2025, 1:35:43 PM
Fundamental Rating

2

Taking everything into account, INTS scores 2 out of 10 in our fundamental rating. INTS was compared to 530 industry peers in the Biotechnology industry. While INTS seems to be doing ok healthwise, there are quite some concerns on its profitability. INTS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INTS has reported negative net income.
In the past year INTS has reported a negative cash flow from operations.
In the past 5 years INTS always reported negative net income.
INTS had a negative operating cash flow in each of the past 5 years.
INTS Yearly Net Income VS EBIT VS OCF VS FCFINTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of INTS (-122.44%) is worse than 80.38% of its industry peers.
INTS has a worse Return On Equity (-162.50%) than 66.04% of its industry peers.
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROIC N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INTS Yearly ROA, ROE, ROICINTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INTS Yearly Profit, Operating, Gross MarginsINTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

INTS has more shares outstanding than it did 1 year ago.
INTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INTS Yearly Shares OutstandingINTS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
INTS Yearly Total Debt VS Total AssetsINTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

INTS has an Altman-Z score of -8.03. This is a bad value and indicates that INTS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INTS (-8.03) is worse than 68.87% of its industry peers.
INTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.03
ROIC/WACCN/A
WACCN/A
INTS Yearly LT Debt VS Equity VS FCFINTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

INTS has a Current Ratio of 3.60. This indicates that INTS is financially healthy and has no problem in meeting its short term obligations.
INTS has a Current ratio (3.60) which is comparable to the rest of the industry.
INTS has a Quick Ratio of 3.60. This indicates that INTS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INTS (3.60) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
INTS Yearly Current Assets VS Current LiabilitesINTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.12% over the past year.
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.27% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.36%
EPS Next 2Y34.63%
EPS Next 3Y19.7%
EPS Next 5Y15.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INTS Yearly Revenue VS EstimatesINTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
INTS Yearly EPS VS EstimatesINTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INTS Price Earnings VS Forward Price EarningsINTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INTS Per share dataINTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as INTS's earnings are expected to grow with 19.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.63%
EPS Next 3Y19.7%

More info and screens

0

5. Dividend

5.1 Amount

INTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INTENSITY THERAPEUTICS INC

NASDAQ:INTS (12/24/2025, 1:35:43 PM)

After market: 0.4083 +0 (+0.42%)

0.4066

-0.01 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)N/A N/A
Inst Owners5%
Inst Owner Change58.89%
Ins Owners9.22%
Ins Owner Change4.01%
Market Cap24.42M
Revenue(TTM)N/A
Net Income(TTM)-11.74M
Analysts80
Price TargetN/A
Short Float %4.58%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.12%
Min EPS beat(2)32.77%
Max EPS beat(2)35.47%
EPS beat(4)3
Avg EPS beat(4)15.34%
Min EPS beat(4)-10.61%
Max EPS beat(4)35.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)34.38%
EPS NQ rev (3m)36.36%
EPS NY rev (1m)24.44%
EPS NY rev (3m)31.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.38
P/tB 3.38
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -8.03
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y70.36%
EPS Next 2Y34.63%
EPS Next 3Y19.7%
EPS Next 5Y15.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.37%
OCF growth 3YN/A
OCF growth 5YN/A

INTENSITY THERAPEUTICS INC / INTS FAQ

What is the fundamental rating for INTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to INTS.


What is the valuation status of INTENSITY THERAPEUTICS INC (INTS) stock?

ChartMill assigns a valuation rating of 0 / 10 to INTENSITY THERAPEUTICS INC (INTS). This can be considered as Overvalued.


How profitable is INTENSITY THERAPEUTICS INC (INTS) stock?

INTENSITY THERAPEUTICS INC (INTS) has a profitability rating of 0 / 10.


What is the financial health of INTENSITY THERAPEUTICS INC (INTS) stock?

The financial health rating of INTENSITY THERAPEUTICS INC (INTS) is 6 / 10.